EGFR and non-small cell lung carcinoma: Epidermal growth factor tyrosine inhibitors (EGFR-TKIs) are considered typical paradigms of targeted therapies in NSCLC, but acquired drug resistance unavoidably limits the clinical efficacy of EGFR-TKIs, which therefore makes fighting against EGFR-TKI resistance an absorbing topic for NSCLC treatment (6, 7).